Deals Report: Elsie, Seres, Marengo build on existing deals to enter new ones

Three small biotechs cut deals with existing partners this week, as oligonucleotide company Elsie accepted a buyout offer from GSK, while Seres sold an approved therapy to Nestlé to extend its cash runway and Marengo and Ipsen struck a new deal.

Elsie Biotechnologies Inc. had revealed fairly little about itself during its lifespan, but a 2023 partnership with GSK plc (LSE:GSK; NYSE:GSK) was among the drivers along its path forward. The pharma first entered a research collaboration with the San Diego-based biotech around its discovery and chemistry technologies, then exercised an option for a non-exclusive licensing deal in February...